The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J(2) delays lipopolysaccharide-induced preterm delivery and reduces mortality in the newborn mouse.
Intrauterine infection is a common trigger for preterm birth and is also a risk factor for the subsequent development of neurodevelopmental abnormalities in the neonate. Bacterial lipopolysaccharide (LPS) binds to toll-like receptor-4 (TLR-4) to activate proinflammatory signaling pathways, which are implicated in both preterm delivery and antenatal brain injury. The transcription factor nuclear factor-kappaB (NF-kappaB) is a key player in the orchestration of the inflammatory response and has a central role in parturition. Here we show that intrauterine administration of TLR-4-specific LPS to pregnant mice results in the activation of NF-kappaB in the maternal uterus and the fetal brain, up-regulation of proinflammatory proteins cyclooxygenase-2, chemokine ligand 1, ChemoKine (C-C motif) ligand 2, and cytosolic phospholipase A(2) in myometrium, and induction of preterm delivery. 15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) is an antiinflammatory prostaglandin that plays a role in promoting the resolution of inflammation. We report that coadministration of 15d-PGJ(2) and LPS to pregnant mice delays LPS-induced preterm delivery and confers protection from LPS-induced fetal mortality. This is associated with inhibition of myometrial NF-kappaB, cytosolic phospholipase A(2), and c-Jun N-terminal kinase activation, and of inflammatory protein synthesis. Therefore 15d-PGJ(2) has anti-inflammatory effects via inhibition of multiple aspects of inflammation-driven TRL-4 signaling pathway. Thus, 15d-PGJ(2) or compounds with similar antiinflammatory functions may have potential as therapeutic agents in the management of preterm labor with the added advantage of preventing detrimental effects to the fetus that may result from infection/inflammation.
Pirianov
Grisha
G
Imperial College Parturition Research Group, Department of Reproductive Biology, Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, London, UK. g.pirianov@imperial.ac.uk
Waddington
Simon N
SN
Lindström
Tamsin M
TM
Terzidou
Vasiliki
V
Mehmet
Huseyin
H
Bennett
Phillip R
PR
D000818:Animals; D000831:Animals, Newborn; D021461:Animals, Outbred Strains; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D003517:Cyclopentanes / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D005260:Female; D007249:Inflammation / Q000150:complications; D008070:Lipopolysaccharides / Q000009:adverse effects*; D051379:Mice; D009215:Myometrium / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D016328:NF-kappa B / Q000378:metabolism; D007752:Obstetric Labor, Premature / Q000139:chemically induced / Q000401:mortality* / Q000517:prevention & control*; D054467:Phospholipases A2 / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D011247:Pregnancy; D015230:Prostaglandin D2 / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D014591:Uterine Diseases / Q000188:drug therapy / Q000209:etiology; D014599:Uterus / Q000378:metabolism / Q000473:pathology
C097240:15-deoxy-delta(12,14)-prostaglandin J2; D000893:Anti-Inflammatory Agents; D003517:Cyclopentanes; D008070:Lipopolysaccharides; D016328:NF-kappa B; D054467:Phospholipases A2; D015230:Prostaglandin D2